Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity
Chronic myeloid leukemia (CML) is a myeloproliferative disease caused by the acquisition of t(9;22) generating the fusion tyrosine kinase BCR::ABL1. However, despite the crucial role of this protein in the dysregulation of numerous signal transduction pathways, a direct measure of BCR::ABL1 kinase a...
Main Authors: | Christian Boni, Massimiliano Bonifacio, Marzia Vezzalini, Luigi Scaffidi, Luisa Tomasello, Laurie L. Parker, Diego Boscarino, Dino Paladin, Mauro Krampera, Claudio Sorio |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-06-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.904510/full |
Similar Items
-
BCR-ABL kinase domain mutations in CML patients, experience from a tertiary care center in North India
by: Akhilesh S, et al.
Published: (2024-01-01) -
Computational Identification of BCR-ABL Oncogenic Signaling as a Candidate Target of Withaferin A and Withanone
by: Vidhi Malik, et al.
Published: (2022-01-01) -
BCR-ABL gene amplification in patients with chronic myeloid leukemia and imatinib resistance
by: S. I. Kutzev, et al.
Published: (2022-11-01) -
Fluorescence in situ hybridization patterns of BCR/ABL1 fusion in chronic myelogenous leukemia at diagnosis
by: Poonam P Jain, et al.
Published: (2012-01-01) -
AS1041, a novel derivative of marine natural compound Aspergiolide A, induces senescence of leukemia cells via oxidative stress-induced DNA damage and BCR-ABL degradation
by: Xuxiu Lu, et al.
Published: (2024-02-01)